|
|
 |
|
Viewing report
|
|
|
|
GV1001 (Pancreatic Cancer) - Analysis and Forecasts to 2020
GlobalData, Nov 2011, Pages: 32
GV1001 (Pancreatic Cancer) - Analysis and Forecasts to 2020
Summary
GlobalData’s pharmaceuticals report, “GV1001 (Pancreatic Cancer) - Analysis and Forecasts to 2020” provides GV1001 sales forecasts for the UK. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Pancreatic Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the UK
- Analysis and review of GV1001 including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of GV1001 including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts for 2014-2020 for GV1001 in the UK
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Keywords
GV1001, tertomotide, Pancreatic cancer, Sales forecast, phase III, phase 3, pipeline, GVAX, HyperAcute Pancreas, Irinotecan, Sutent, GV1001, Afinitor, Avastin, AMG479, Abraxane, Masitinib, Gemzar, Nexavar, S-1, Tarceva, Certican, vaccine, Kael-Gemvax, telomerase
|
|
|
|
